IRIS Accounts Production v26.2.0.496 10451870 director 1.1.25 31.12.25 31.12.25 false true false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh104518702024-12-31104518702025-12-31104518702025-01-012025-12-31104518702023-12-31104518702024-01-012024-12-31104518702024-12-3110451870ns15:EnglandWales2025-01-012025-12-3110451870ns14:PoundSterling2025-01-012025-12-3110451870ns10:Director12025-01-012025-12-3110451870ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3110451870ns10:SmallEntities2025-01-012025-12-3110451870ns10:AuditExempt-NoAccountantsReport2025-01-012025-12-3110451870ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-3110451870ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-3110451870ns10:FullAccounts2025-01-012025-12-3110451870ns10:RegisteredOffice2025-01-012025-12-3110451870ns5:CurrentFinancialInstruments2025-12-3110451870ns5:CurrentFinancialInstruments2024-12-3110451870ns5:ShareCapital2025-12-3110451870ns5:ShareCapital2024-12-3110451870ns5:RetainedEarningsAccumulatedLosses2025-12-3110451870ns5:RetainedEarningsAccumulatedLosses2024-12-3110451870ns5:ComputerEquipment2025-01-012025-12-3110451870ns5:ComputerEquipment2024-12-3110451870ns5:ComputerEquipment2025-12-3110451870ns5:ComputerEquipment2024-12-3110451870ns5:CostValuationns5:ListedExchangeTraded2024-12-3110451870ns5:CostValuationns5:UnlistedNon-exchangeTraded2024-12-3110451870ns5:AdditionsToInvestmentsns5:ListedExchangeTraded2025-12-3110451870ns5:AdditionsToInvestmentsns5:UnlistedNon-exchangeTraded2025-12-3110451870ns5:DisposalsRepaymentsInvestmentsns5:ListedExchangeTraded2025-12-3110451870ns5:DisposalsRepaymentsInvestmentsns5:UnlistedNon-exchangeTraded2025-12-3110451870ns5:CostValuationns5:ListedExchangeTraded2025-12-3110451870ns5:CostValuationns5:UnlistedNon-exchangeTraded2025-12-3110451870ns5:ListedExchangeTraded2025-12-3110451870ns5:UnlistedNon-exchangeTraded2025-12-3110451870ns5:ListedExchangeTraded2024-12-3110451870ns5:UnlistedNon-exchangeTraded2024-12-3110451870ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-3110451870ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-31
REGISTERED NUMBER: 10451870 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

JCSMED LIMITED

JCSMED LIMITED (REGISTERED NUMBER: 10451870)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


JCSMED LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2025







DIRECTOR: J C Sijmonsbergen





REGISTERED OFFICE: 15 West Street
Brighton
East Sussex
BN1 2RL





REGISTERED NUMBER: 10451870 (England and Wales)





ACCOUNTANTS: Galloways Accounting Limited
15 West Street
Brighton
East Sussex
BN1 2RL

JCSMED LIMITED (REGISTERED NUMBER: 10451870)

BALANCE SHEET
31 DECEMBER 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 - -
Investments 5 388,968 436,681
Investment property 6 532,682 532,682
921,650 969,363

CURRENT ASSETS
Debtors 7 83,222 55,426
Cash at bank 838,198 593,070
921,420 648,496
CREDITORS
Amounts falling due within one year 8 103,883 58,002
NET CURRENT ASSETS 817,537 590,494
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,739,187

1,559,857

CAPITAL AND RESERVES
Called up share capital 1,300,000 1,300,000
Retained earnings 439,187 259,857
1,739,187 1,559,857

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 September 2026 and were signed by:





J C Sijmonsbergen - Director


JCSMED LIMITED (REGISTERED NUMBER: 10451870)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025


1. STATUTORY INFORMATION

Jcsmed Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 33.3% straight line

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 11 (2024 - 11 ) .

JCSMED LIMITED (REGISTERED NUMBER: 10451870)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025


4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 January 2025
and 31 December 2025 7,366
DEPRECIATION
At 1 January 2025
and 31 December 2025 7,366
NET BOOK VALUE
At 31 December 2025 -
At 31 December 2024 -

5. FIXED ASSET INVESTMENTS
Listed Unlisted
investments investments Totals
£    £    £   
COST OR VALUATION
At 1 January 2025 436,681 - 436,681
Additions - 87,997 87,997
Disposals (146,483 ) - (146,483 )
At 31 December 2025 290,198 87,997 378,195
PROVISIONS

Revaluation adjustments (10,773 ) - (10,773 )
At 31 December 2025 (10,773 ) - (10,773 )
NET BOOK VALUE
At 31 December 2025 300,971 87,997 388,968
At 31 December 2024 436,681 - 436,681


6. INVESTMENT PROPERTY
Total
£   
FAIR VALUE
At 1 January 2025
and 31 December 2025 532,682
NET BOOK VALUE
At 31 December 2025 532,682
At 31 December 2024 532,682

JCSMED LIMITED (REGISTERED NUMBER: 10451870)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025


7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Amounts owed by group undertakings 82,459 48,441
Other debtors - 4,920
Directors' current accounts 763 2,065
83,222 55,426

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors - 1,347
Tax 52,101 34,278
Social security and other taxes 2,004 1,943
VAT 34,173 4,829
Other creditors 14,375 14,375
Accruals and deferred income 1,230 1,230
103,883 58,002